THC/CBD Spray Reduced Cancer Pain That Opioids Could Not Fully Control
In 177 cancer patients with opioid-refractory pain, THC/CBD extract spray significantly reduced pain scores compared to placebo, with 43% of patients achieving at least 30% pain reduction versus 21% on placebo.
Quick Facts
What This Study Found
One hundred seventy-seven cancer patients whose pain was inadequately controlled by opioids were randomized to THC/CBD extract spray (60 patients), THC-only extract spray (58 patients), or placebo (59 patients) for two weeks.
The THC/CBD group showed statistically significant pain improvement compared to placebo (mean change -1.37 vs -0.69 on a numerical rating scale). The THC-only group showed improvement (-1.01 vs -0.69) but did not reach significance.
Twice as many THC/CBD patients achieved clinically meaningful pain reduction (30% or more): 43% versus 21% on placebo. The THC-only group response rate (23%) was similar to placebo.
Opioid background medication doses did not change across groups, confirming the cannabinoid effect was additive rather than opioid-replacing.
One negative finding: THC/CBD worsened nausea and vomiting scores compared to placebo (p=0.02).
Key Numbers
177 patients. THC/CBD pain reduction: -1.37 vs placebo -0.69 (significant). THC alone: -1.01 (not significant). 30% responders: THC/CBD 43% vs placebo 21% (significant). THC alone 23% (not significant). Nausea worsened with THC/CBD (p=0.02).
How They Did This
Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial. 177 patients with advanced cancer pain inadequately controlled by chronic opioids. Two-week treatment with THC/CBD extract, THC extract, or placebo spray. Primary outcome: change in mean pain NRS score.
Why This Research Matters
This was one of the strongest clinical trials supporting cannabinoids as adjunctive pain therapy in cancer patients already on opioids. The finding that THC/CBD was effective but THC alone was not highlighted the importance of CBD in the formulation.
The Bigger Picture
Cancer pain management remains inadequate for many patients despite opioid therapy. This trial showed that adding a THC/CBD spray could provide meaningful additional relief, supporting Sativex's later approval for cancer pain in some jurisdictions.
What This Study Doesn't Tell Us
Two-week trial may not reflect long-term outcomes. The THC-only group's failure to reach significance raises questions about why CBD was necessary. Nausea worsening with THC/CBD is a significant concern. Open-label extension data were not reported in this paper.
Questions This Raises
- ?Why was THC/CBD effective but THC alone was not?
- ?Would longer treatment produce sustained benefit?
- ?Can the nausea side effect be managed?
- ?What is the optimal dosing for cancer pain?
Trust & Context
- Key Stat:
- 43% of THC/CBD patients achieved 30%+ pain reduction vs 21% on placebo; THC alone was not significant
- Evidence Grade:
- Well-designed multicenter RCT with adequate sample size (177). Two-week duration and the nausea side effect are limitations.
- Study Age:
- Published in 2010. This trial was pivotal in the regulatory approval of Sativex for cancer pain in several countries.
- Original Title:
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
- Published In:
- Journal of pain and symptom management, 39(2), 167-79 (2010)
- Authors:
- Johnson, Jeremy R(2), Burnell-Nugent, Mary(2), Lossignol, Dominique(2), Ganae-Motan, Elena Doina, Potts, Richard, Fallon, Marie T
- Database ID:
- RTHC-00423
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Why did the combination of THC and CBD work better than THC alone?
The mechanism is not fully clear from this trial, but CBD may enhance THC analgesic effects, reduce some THC side effects, or contribute its own pain-relieving properties. The finding reinforces that the combination is more than the sum of its parts for pain management.
Did patients stop needing opioids?
No. Opioid doses remained unchanged across all groups. The cannabinoid spray provided additional pain relief on top of existing opioid therapy, not as a replacement. This additive effect is clinically valuable for patients whose pain is not adequately controlled by opioids alone.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00423APA
Johnson, Jeremy R; Burnell-Nugent, Mary; Lossignol, Dominique; Ganae-Motan, Elena Doina; Potts, Richard; Fallon, Marie T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.. Journal of pain and symptom management, 39(2), 167-79. https://doi.org/10.1016/j.jpainsymman.2009.06.008
MLA
Johnson, Jeremy R, et al. "Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.." Journal of pain and symptom management, 2010. https://doi.org/10.1016/j.jpainsymman.2009.06.008
RethinkTHC
RethinkTHC Research Database. "Multicenter, double-blind, randomized, placebo-controlled, p..." RTHC-00423. Retrieved from https://rethinkthc.com/research/johnson-2010-multicenter-doubleblind-randomized-placebocontrolled
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.